Coagulation

EQS-News: Defence Therapeutics Inc.: DEFENCE POSITIONED TO BEGIN ITS ANTI-CANCER ACCUTOXTM PHASE I TRIAL WITH SUCCESSFUL COMPLETION OF GLP STUDIES

Retrieved on: 
Sunday, December 18, 2022
Breast cancer, Coagulation, Cell, Tmax, DNA repair, Melanoma, Neoplasm, Survival rate, Reactive oxygen species, GLP, Mortality, Animal, Laboratory rat, FDA, Catastrophic illness, Safety, DNA, Engineering, Cancer, Hardness, ADC, RATS, Dog, Control, Systemic inflammation, Female, Mouse, Erythema, Urine test strip, Vaccine, News, Urine, CSE, Defense, Disease, Toxicity, USD, Infection, Growth, Plasma, Therapy, Injection, Male, Patient, Security (finance), Pharmaceutical industry

In the past 16 months, Defence engineered a large library of AccumTM variants exhibiting differential effects on both immune and cancer cells.

Key Points: 
  • In the past 16 months, Defence engineered a large library of AccumTM variants exhibiting differential effects on both immune and cancer cells.
  • Interestingly, AccuTOXTM administration synergises with different immune-checkpoints (anti-PD-1, anti-CTLA4 and anti-CD47) making it a highly mouldable molecule adaptable to a myriad of solid cancer indications.
  • GLP studies in rodents revealed no adverse effects for AccuTOXTM.
  • Upon completing the GLP study in rats, Defence followed up with a second set of GLP studies in Beagle dogs.

Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study

Retrieved on: 
Thursday, December 15, 2022
Immunotherapy, Coagulation, GLP, Foralumab, CNS, CD3, MS, ALS, FDA, Safety, Amyotrophic lateral sclerosis, Central nervous system, Mab, Good laboratory practice, Human, Pharmacist, Hematology, Patient, Pharmaceutical industry

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces completion of the in-life portion of a 13-week, Good Laboratory Practice (GLP) foralumab intranasal pre-clinical study in transgenic HuGEMM CD3 mouse models.

Key Points: 
  • NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces completion of the in-life portion of a 13-week, Good Laboratory Practice (GLP) foralumab intranasal pre-clinical study in transgenic HuGEMM CD3 mouse models.
  • The study showed that intranasal foralumab, administered to the transgenic mice at doses up to 50 µg/rodent, was clinically well tolerated.
  • Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, “Completion of this preclinical trial is a critical milestone for Tiziana.
  • However, by using HuGEMM CD3 transgenic mice who express human CD3, we were able to study the 13-week pre-clinical safety profile of intranasal foralumab in an elegant and validated manner.

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Retrieved on: 
Saturday, December 10, 2022
Haemophilia A, Hemostasis, Bleeding, Protein, Disorder, Annual report, Person, FDA, DRS, Omicron, Safety, Arthropathy, Maintenance, Coagulation, Pharmacokinetics, Factor VIII, Haemophilia, ASH, Hemarthrosis, Thrombin, Doctor of Philosophy, APC, VIII, Joint, Factor IX, PWH, Research, OLE, Risk, Male, COVID-19, Volunteering, Patient, Coagulopathy, Pharmaceutical industry, Delta

The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).

Key Points: 
  • The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).
  • Yver and Baglin share the OLE data slides presented at ASH and discuss the SerpinPC registrational program within a recorded webcast now available on the Company’s website at https://investors.centessa.com/events-presentations .
  • SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.
  • Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients.

Aronora CEO Named National Academy of Inventors Fellow

Retrieved on: 
Thursday, December 8, 2022
OHSU, Thrombosis, TPA, Oregon Health & Science University, National academy, Hemostasis, Bleeding, Quality of life, Prevalence, Fellows, FDA, School, NAI, University, Economic development, Death, Coagulation, Stroke, Experiment, Doctor of Philosophy, Innovation, Medical school, National Academies of Sciences, Engineering, and Medicine, Biomedicine, Research, Heparin, Biomedical engineering, Therapy, National Academy of Inventors, Pharmaceutical industry, Science, Invention, Medicine, Engineering

PORTLAND, Ore., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Erik Tucker, Ph.D., joins an elite group of inventors with his election to the National Academy of Inventors.

Key Points: 
  • PORTLAND, Ore., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Erik Tucker, Ph.D., joins an elite group of inventors with his election to the National Academy of Inventors.
  • "I am truly honored to be elected as a Fellow of the National Academy of Inventors, and proud to join an exceptional group of distinguished Fellows worldwide," said Tucker.
  • The National Academy of Inventors Fellows Program recognizes inventors who have demonstrated prolific innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.
  • Election as an NAI Fellow is the highest professional distinction accorded to academic inventors.

Global Coagulation Testing Market to Reach $3.8 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 12, 2022
Research, Science, Coagulation, Coagulation testing, COVID-19, Growth, Pet

In the changed post COVID-19 business landscape, the global market for Coagulation Testing estimated at US$2.7 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 4.8% over the period 2020-2027.

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Coagulation Testing estimated at US$2.7 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 4.8% over the period 2020-2027.
  • Consumables, one of the segments analyzed in the report, is projected to record 5.1% CAGR and reach US$3.1 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $742.5 Million, While China is Forecast to Grow at 7.2% CAGR
    The Coagulation Testing market in the U.S. is estimated at US$742.5 Million in the year 2020.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$778.1 Million by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027.

Global Blood Plasma Derivatives Market Report 2022: Rising Prevalence of Hemophilia Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Health, Biotechnology, Hormone, Respiration, Salt, Mineral, Hypogammaglobulinemia, Virus, Antibody, Osmotic pressure, Serum, Thermoregulation, Ageing, Plant, Haemophilia, Infection, Factor IX, Protein, Plasma, Muscle, United Nations, Hepatitis B, FBS, Factor VIII, Haemophilia A, DNA, Hospital, Coagulopathy, Nutrient, Vitamin, Bleeding, Incidence, Blood, Joint, Genetic engineering, Molecular biology, VIII, Application, Coagulation, Hepatitis C, Protease, HIV, Trauma, IX, Blood product, Vaccine

The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.

Key Points: 
  • The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.
  • Blood plasma derivatives are specific protein concentrates extracted from plasma using a fractionation technique.
  • In addition, blood plasma derivatives aid in boosting nutrition, regulating body temperature and blood coagulation, maintaining osmotic pressure, improving respiration as well as excretion, and balancing acid-base levels.
  • In hospitals, clinics, diagnostic facilities, and blood transfusion centers, blood plasma derivatives are widely preserved.

Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting

Retrieved on: 
Tuesday, December 6, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, Therapy, Norwest Venture Partners, RA, SC, Clinical trial, MD, Haemophilia, Coagulation, Doctor of Philosophy, Competent authority, Society, Patient, Entrepreneurship, Thrombin, Biology, Vega, APC, Coagulopathy, Von Willebrand factor, Bleeding, VWF, VWD, Trial of the century, Von Willebrand disease, Fibrinolysis, Degenerative disease, Pharmacokinetics, Blood, ASH, Protein S, Pharmaceutical industry

Vega was spun out of its parent company, Star Therapeutics , to advance the discovery and development of antibody therapies for patients with blood disorders, starting with von Willebrand disease (VWD).

Key Points: 
  • Vega was spun out of its parent company, Star Therapeutics , to advance the discovery and development of antibody therapies for patients with blood disorders, starting with von Willebrand disease (VWD).
  • Vega will disclose the first public information about VGA039 in a podium presentation on December 12th at the ASH Annual Meeting in New Orleans.
  • In VWD, defective or low amounts of von Willebrand factor (VWF) leads to insufficient platelet adhesion and unstable clot formation.
  • Vega Therapeutics is a clinical stage biotechnology company developing novel, first-in-class therapies for rare blood disorders with overlooked patient needs, starting with von Willebrand disease (VWD).

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

Retrieved on: 
Thursday, November 17, 2022
COVID-19, Degenerative disease, Diagnosis, ASN, American Society of Nephrology, BYU College of Life Sciences, Immunoglobulin A, FRCP, BK virus, Union, ESRD, Food, University, Autoantibody, Dialysis, Radar, Therapy, College, B-cell activating factor, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, TACI, Clinical trial, Cytokine, Biomarker, Surrogate, Coagulation, Chronic kidney disease, Standard of care, University of Leicester, Lupus nephritis, Society, International, Security (finance), B cell, Barratt, Research, BK, Kidney failure, Polyomaviridae, KOL, Vera, Pharmaceutical industry, Vaccine, IgA nephropathy

BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL) webinar on IgA nephropathy (IgAN), a common cause of kidney failure. The webinar will be held on Monday, November 28, 2022 at 2:00pm ET.

Key Points: 
  • Recent data presented by Dr. Barratt at the American Society of Nephrology (ASN) Kidney Week 2022 showed atacicept reduced immune complex levels in patients with IgAN.
  • In addition, the Vera Therapeutics leadership team will provide an overview of the ongoing Phase 2b ORIGIN trial of atacicept in IgAN and the Companys pipeline.
  • If the data from the ORIGIN trial are supportive, Vera Therapeutics expects to initiate a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Retrieved on: 
Monday, November 14, 2022
Heel, Health, Infection, World Diabetes Day, Laboratory, Norfolk and Norwich University Hospital, Pharmacy, GP, Internal medicine, Norwich Medical School, Degenerative disease, Disease, SD, IDF, Diabetes, CV, Glycated hemoglobin, UEA, Risk, School, Coagulation, Patient, Pharmaceutical industry, Platform

Used alongside the LumiraDx Platform, the test monitors known diabetic patients HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.

Key Points: 
  • Used alongside the LumiraDx Platform, the test monitors known diabetic patients HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.
  • 1 The portability and flexibility of the LumiraDx Platform enables the LumiraDx HbA1c test to address the growing clinical need for accessible and reliable HbA1c testing in the community healthcare setting to aid in quicker clinical decision making.
  • The LumiraDx HbA1c test has a reportable range of 20 - 130 mmol/mol HbA1c (4.0 - 14.0% HbA1c).
  • The availability of an immediate, lab-comparable HbA1c test has been shown to improve patient outcomes through improved diabetes management.

Worldwide In Vitro Diagnostic Tests Market Report 2022 with Profiles of 200+ Companies - Financial Results, Product Launches, Company History and Strategic Plans - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 22, 2022
Health, Biotechnology, Infection, Non-functional testing, Blood bank, Government, Point of care, Projection, Histology, Size, Research, IVD, Financial result, Market, NYSE Arca Major Market Index, Medical device, Speciality chemicals, Retail, Coagulation, Hematology, Immunoassay

The 15th edition of The Worldwide Market for In Vitro Diagnostic Tests provides readers with reliable estimates, real-world forecasts, and insights needed to understand the IVD market in its entirety.

Key Points: 
  • The 15th edition of The Worldwide Market for In Vitro Diagnostic Tests provides readers with reliable estimates, real-world forecasts, and insights needed to understand the IVD market in its entirety.
  • The full assessment of the IVD diagnostic market makes The Worldwide Market for In Vitro Diagnostic Tests the most trusted report by top companies in the industry.
  • The in vitro diagnostics market is a global one, and The Worldwide Market for In Vitro Diagnostic (IVD) Tests reflects the international scope of the in vitro diagnostics market size.
  • The report concentrates over a thousand pages on detailed and tiered profiles of companies in the in vitro diagnostics market.